STAT

The global responders: Who is leading the charge against the coronavirus outbreak

As concerns mount over the novel coronavirus, public health officials around the globe have launched a massive response. Here's who is involved.
World Health Organization (WHO) Health Emergencies Program head Michael Ryan, WHO Director-General Tedros Adhanom Ghebreyesus and WHO Chair of Emergency Committee on Ebola Robert Steffen attend a combined news conference following as two-day international conference on COVID-19 coronavirus vaccine research.

As concerns mount over the coronavirus that first emerged in China, public health officials there and around the globe have launched a massive response.

The nature of that response has varied. In China, officials are trying to contain the virus. In countries that have seen local transmission, including Germany and Singapore, the goal has been to stamp out flare-ups. And in much of the world that hasn’t yet seen much spread of the virus yet, public health officials are readying a strategy in case they do.

So who’s leading the charge?

What follows is a list of some of the most important players, from a handful of the agencies involved. The list is hardly comprehensive. And selection is not meant to amplify these people’s importance over that of others.

In fact, some of the most vital responders do not appear here: the countless frontline health care workers who are trying to save lives and prevent new cases, all while putting their own safety on the line.

Read more: U.S. biotechs fear the coronavirus

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min readChemistry
STAT+: Pharmalittle: We’re Reading About Fake Studies, AbbVie Investing In Psychedelics, And More
Fake studies have flooded publishers of top scientific journals,. leading to thousands of retractions and millions of dollars in lost revenue.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
STAT1 min read
Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.

Related Books & Audiobooks